Update on primary ovarian insufficiency in adolescents

Current Opinion in Pediatrics

Volumn 27, Issue 4, 2015, Pages 511-519

  Gordon, Catherine M ^a   Kanaoka, Tsuzuki ^a,b   Nelson, Lawrence M ^c  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

amenorrhea; genetic origins; Keywords adolescence; premature menopause; premature ovarian failure; primary ovarian insufficiency

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; ESTRADIOL; FOLLITROPIN RECEPTOR; FORKHEAD BOX L2; FRAGILE X MENTAL RETARDATION PROTEIN; MEDROXYPROGESTERONE ACETATE; NUCLEAR RECEPTOR SUBFAMILY 5 GROUP A MEMBER 1; PROTEIN; UNCLASSIFIED DRUG; FMR1 PROTEIN, HUMAN;

ADOLESCENT; EMOTIONAL STABILITY; FAMILY PLANNING; FAMILY SYSTEMS THEORY; FEMALE; GALACTOSEMIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; IATROGENIC DISEASE; MENOPAUSE; NONHUMAN; OVARY FUNCTION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSDERMAL PATCH; TURNER SYNDROME; AMENORRHEA; EARLY DIAGNOSIS; ESTROGEN THERAPY; FERTILITY PRESERVATION; GENETIC COUNSELING; INFERTILITY, FEMALE; PARENT; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; PSYCHOLOGY;

ADOLESCENT; AMENORRHEA; EARLY DIAGNOSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FERTILITY PRESERVATION; FRAGILE X MENTAL RETARDATION PROTEIN; GENETIC COUNSELING; HUMANS; INFERTILITY, FEMALE; PARENTS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84959494055     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000236     Document Type: Review

References (75)

1. Nelson LM. Primary ovarian insufficiency. N Engl J Med 2009; 360.6: 606-614
2. American College of Obstetricians and Gynecologists. Committee opinion no. 605: Primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014; 124: 193-197
3. American College of Obstetricians and Gynecologists. Committee Opinion no. 349: Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006; 108: 1323-1328
4. Sadeghi MR. New hopes for the treatment of primary ovarian insufficiency/premature ovarian failure. J Reprod Fertil 2013; 14: 1-2
5. Bakhsh H, Dei M, Bucciantini S, et al. Premature ovarian insufficiency in young girls: repercussions on uterine volume and bone mineral density. Gynecol Endocrinol 2014; 31: 65-69
6. Geckinli BB, Toksoy G, Sayar C, et al. Prevalence of X-aneuploidies, Xstructural abnormalities and 46, XY sex reversal in Turkish women with primary amenorrhea or premature ovarian insufficiency. Eur J Obstet Gynecol Reprod Biol 2014; 182: 211-215
7. Marozzi A, Vegetti W, Manfredini E, et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod 2000; 15.1: 197-202
8. Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril 2005; 84: 958-965
9. Bates GW, Bowling M. Physiology of the female reproductive axis. Periodontol 2000 2013; 61: 89-102
10. Gold EB, Crawford SL, Avis NE, etal.Factorsrelatedtoageatnaturalmenopause: longitudinal analyses from SWAN. Am J Epidemiol 2013; 178: 70-83
11. Hubayter ZR, Popat V, Vanderhoof VH, et al. A prospective evaluation of antral follicle function in women with 46, XX spontaneous primary ovarian insufficiency. Fertil Steril 2010; 94: 1769-1774
12. Covington SN, Hillard PJ, Sterling EW, Nelson LM. A family systems approach to primary ovarian insufficiency. J Pediatr Adolesc Gynecol 2011; 24: 137-141
13. Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994; 79: 1470-1475
14. Aittomä ki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82: 959-968
15. Nance WE. The genetics of deafness. Ment Retard Dev Disabil Res Rev 2003; 9: 109-119
16. Simpson JL. Genetics of female infertility due to anomalies of the ovary and Mü llerian ducts. Methods Mol Biol 2014; 1154: 39-73
17. Wood-Trageser MA, Gurbuz F, Yatsenko SA, et al. MCM9 mutations are associated with ovarian failure, short stature, and chromosomal instability. Am J Hum Genet 2014; 95: 754-762
18. AlAsiri S, Basit S, Wood-Trageser MA, et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest 2015; 125: 258-262
19. De Vries L, Behar DM, Smirin-Yosef P, et al. Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. J Clin Endocrinol Metab 2014; 99: E2129-E2132
20. Wang J, Zhang W, Jiang H, Wu BL. Mutations in HFM1 in recessive primary ovarian insufficiency. N Engl J Med 2014; 370: 972-974
21. Caburet S, Arboleda VA, Llano E, et al. Mutant cohesin in premature ovarian failure. N Engl J Med 2014; 370: 943-949
22. Bertapelli F, De Azevedo Barros-Filho A, De Góes Monteiro Antonio MAR, et al. Growth curves for girls with Turner syndrome. Biomed Res Int 2014; 2014: 1-8
23. Castronovo C, Rossetti R, Rusconi D, et al. Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. Hum Reprod 2014; 29: 368-379
24. Lu C, Lin L, Tan H, et al. Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum Mol Genet 2012; 21: 5039-5047
25. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010; 19: R83-R89
26. Fortuño C, Labarta E. Genetics of primary ovarian insufficiency: a review. J Assist Reprod Genet 2014; 31: 1573-1585
27. Murray A, Schoemaker MJ, Bennett CE, et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet Med 2013; 16: 19-24
28. Fridovich-Keil JL, Gubbels CS, Spencer JB, et al. Ovarian function in girls and women with GALT-deficiency galactosemia. J Inherit Metab Dis 2011; 34: 357-366
29. Persani L, Rossetti R, Di Pasquale E, et al. The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Hum Reprod Update 2014; 20: 869-883
30. Tiotiu D, Alvaro Mercadal B, Imbert R, et al. Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Hum Reprod 2010; 25: 1581-1587
31. Laissue P, Lakhal B, Banayoun BA, et al. Functional evidence implicating FOXL2 in nonsyndromic premature ovarian failure and in the regulation of the transcription factor OSR2. J Med Genet 2009; 46: 455-457
32. Verdin H, De Baere E. FOXL2 impairment in human disease. Horm Res Paediatr 2012; 77: 2-11
33. Lourenço D, Brauner R, Lin L, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 2009; 360: 1200-1210
34. Voican A, Bachelot A, Bouligand J, et al. NR5A1 (SF-1) mutations are not a major cause of primary ovarian insufficiency. J Clin Endocrinol Metab 2013; 98: E1017-E1021
35. Aittomä ki K, Herva R, Stenman UH, et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996; 81: 3722-3726
36. Layman LC, Amde S, Cohen DP, et al. The Finnish follicle-stimulating hormone receptor gene mutation is rare in North American women with 46, XX ovarian failure. Fertil Steril 1998; 69: 300-302
37. Loutradis D, Patsoula E, Stefanidis K, et al. Follicle-stimulating hormone receptor gene mutations are not evident in Greek women with premature ovarian failure and poor responders. Gynecol Obstet Invest 2005; 61: 56-60
38. Vilodre LC, Kohek MB, Spritzer PM. Screening of follicle-stimulating hormone receptor gene in women with premature ovarian failure in southern Brazil and associations with phenotype. Endocrinol Invest 2008; 31: 552-557
39. Woad KJ, Prendergast D, Winship IM, Shelling AN. FSH receptor gene variants are rarely associated with premature ovarian failure. Reprod Biomed Online 2013; 26: 396-399
40. Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014; 13: 427-430
41. Pogačnik RK, Vrtovec HM, Vizjak A, et al. Possible role of autoimmunity in patients with premature ovarian insufficiency. Int J Fertil Steril 2014; 7: 281-290
42. Novosad JA, Kalantaridou SN, Tong Z, Nelson LM. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003; 3: 2
43. Alimohammadi M, Bjö rklund P, Hallgren A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008; 358: 1018-1028
44. Tong ZB, Nelson LM. A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure. Endocrinology 1999; 140: 3720-3726
45. Tong ZB, Gold L, Pfeifer KE, et al. Mater, a maternal effect gene required for early embryonic development in mice. Nat Genet 2000; 26: 267-268
46. Betterle C, Volpato M, Rees Smith B, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997; 82: 932-938
47. Brozzetti A, Alimohammadi M, Morelli S, et al. Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's disease. J Clin Endocrinol Metab 2015; 100: 1941-1948; doi: 10.1210/jc.2014-3571. [Epub ahead of print
48. Sapre S, Thakur R. Lifestyle and dietary factors determine age at natural menopause. J Midlife Health 2014; 5: 3-5
49. Ertunc D, Tok EC, Aytan H, Gozukara YM. Passive smoking is associated with lower age at menopause. Climacteric 2015; 18: 47-52
50. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Women's Health 2014; 6: 235-243
51. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7: 535-543
52. Bresters D, Emons JA, Nuri N, et al. Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatr Blood Cancer 2014; 61: 2048-2053
53. Sanfilippo JS. Is the menstrual cycle truly a vital sign?. J Pediatr Adolesc Gynecol 2014; 27: 307-308
54. Hillard PJA. Menstruation in adolescents: what do we know?. And what do we do with the information?. J Pediatr Adolesc Gynecol 2014; 27: 309-319
55. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12 (1 Pt 2): 77-126
56. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53: 804-810
57. Practice Committee of the American Society for Reproductive Medicine Current evaluation of amenorrhea. Fertil Steril 2004; 82: 266-272
58. Alzubaidi NH, Chapin HL, Vanderhoof VH, et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99 (5 pt 1): 720-725
59. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogendeficient young women. J Clin Endocrinol Metab 2009; 94: 2277-2283
60. Allen EG, Grus WE, Narayan S, et al. Approaches to identify genetic variants that influence the risk for onset of fragile X-associated primary ovarian insufficiency (FXPOI): a preliminary study. Front Genet 2014; 5: 260
61. Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005; 83: 1734-1741
62. Gilbert RM. The eight concepts of Bowen theory. Falls Church, VA: Leading Systems; 2006
63. Covington SN, Martinez PE, Popat V, et al. The psychology of antecedents to adult reproductive disorders in adolescent girls. Ann NY Acad Sci 2008; 1135: 155-162
64. Sterling EW, Nelson LM. From victim to survivor to thriver: helping women with primary ovarian insufficiency integrate recovery, self-management, and wellness. Semin Reprod Med 2011; 29: 353-361
65. DiVasta AD, Gordon CM. Hormone replacement therapy and the adolescent. Curr Opin Obstet Gynecol 2010; 22: 363-368
66. Fish JD. Part 1: hormone replacement for survivors of childhood cancer with ovarian failure -when is it worth the risk?. J Pediatr Adolesc Gynecol 2011; 24: 98-101
67. Hershlag A, Rausch ME, Cohen M. Part 2: Ovarian failure in adolescent cancer survivors should be treated. J Pediatr Adolesc Gynecol 2011; 24: 101-103
68. Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013; 25: 375-381
69. Shah S, Forghani N, Durham E, Neely EK. A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism. Int J Pediatr Endocrinol 2014; 2014: 12
70. Gibbons WE, Moyer DL, Lobo RA, et al. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986; 154: 456-461
71. Bjarnason K, Cerin A, Lindgren R, et al. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 1999; 32: 161-170
72. Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99: 3418-3426
73. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078
74. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432
75. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845